• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • MEI Pharma, KHK to develop and commercialize ME-401 biospectrumasia
    November 26, 2018
    MEI Pharma, Inc. and Kyowa Hakko Kirin Co., Ltd. (KHK), have announced the execution of a license agreement granting KHK exclusive rights to develop and commercialize ME-401 in Japan.
  • MEI Pharma, BeiGene Collaborate on ME-401, Zanubrutinib Combination americanpharmaceuticalreview
    October 12, 2018
    MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of pati

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service